AstraZeneca’s $1.3B CinCor Acquisition Fuels Baxdrostat Breakthrough in Resistant Hypertension

AstraZeneca reported that its investigational drug baxdrostat significantly reduced blood pressure in patients with treatment-resistant hypertension, based on data from a Phase III trial. The positive trial outcomes contributed to a nearly 2% rise in the company’s share price. AstraZeneca projects peak annual sales of baxdrostat could surpass $5 billion, citing potential use both as a standalone treatment and in combination with Farxiga, its established therapy for type 2 diabetes, heart failure, and chronic kidney disease.

Baxdrostat Lowers Systolic Blood Pressure in Patients with Uncontrolled and Resistant Hypertension

AstraZeneca announced baxdrostat met both primary and secondary endpoints in the Phase III BaxHTN trial. The study demonstrated that adding baxdrostat at either a 2mg or 1mg daily dose to standard care significantly and clinically reduced systolic blood pressure at 12 weeks compared to placebo. The trial included 796 adults diagnosed with either uncontrolled hypertension, persistent high blood pressure despite two or more medications, or resistant hypertension, where blood pressure remains elevated despite three or more treatments, including a diuretic.

Participants in the study continued their existing antihypertensive therapy while receiving either one of the two baxdrostat doses or a placebo. The trial’s success builds on AstraZeneca’s acquisition of CinCor Pharma in 2023, through which it gained rights to baxdrostat as part of a broader strategy to expand its cardiovascular and renal disease pipeline.

Baxdrostat is a highly selective aldosterone synthase inhibitor that targets aldosterone, a hormone involved in raising blood pressure. This mechanism represents a novel approach compared to older classes of antihypertensive drugs, such as ACE inhibitors, which do not address hormonal drivers. Given that high blood pressure affects over 1 billion people worldwide, according to the World Health Organization, AstraZeneca views baxdrostat as a potential blockbuster therapy with projected peak annual sales exceeding $5 billion.

Dr. Bryan Williams, Chair of Medicine at University College London, primary investigator, said: “The highly promising BaxHTN Phase III results show that once-daily baxdrostat on top of standard of care can meaningfully lower systolic blood pressure and offer a potential new treatment approach for controlling hypertension, the leading risk factor for cardiovascular disease.”

Drug Targets Aldosterone Dysregulation, with 2mg Dose Achieving Clinically Meaningful Blood Pressure Reduction

AstraZeneca is evaluating baxdrostat in a clinical program involving over 20,000 patients. The drug selectively inhibits aldosterone synthase without disrupting cortisol synthesis, offering a targeted approach to managing high blood pressure. In the BaxHTN trial, baxdrostat not only reduced systolic blood pressure but also helped more patients reach a target of under 130 mmHg, with results showing a favorable safety profile.

The study included a follow-up phase in which researchers re-randomized 300 patients on a 2mg dose to continue treatment or switch to placebo for eight weeks, while monitoring long-term safety over 52 weeks. These extended findings, alongside data on diastolic blood pressure and side effects, will be presented at the European Society of Cardiology Congress in August 2025. AstraZeneca has not yet specified when it will seek U.S. regulatory approval but plans to share the full results at the upcoming medical conference.

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, emphasized the significance of the BaxHTN results, noting that baxdrostat addresses a long-standing gap in innovation by targeting aldosterone dysregulation. As a highly selective, oral aldosterone synthase inhibitor, baxdrostat is being studied as a monotherapy and in combination with dapagliflozin for broader indications. “These findings provide compelling evidence of baxdrostat’s potential to address a critical unmet need by targeting aldosterone dysregulation, bringing a novel mechanism to a field that has seen little innovation in over two decades,” she stated.

Author

Denisse Sandoval

Related Post

Markets & Deals

AstraZeneca Pledges $15 Billion China Investment and Signs Up to $18.5 Billion CSPC Obesity Deal

2026-02-02

Prime

[Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector

2026-01-30

Prime

JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb

2026-01-15